Comprehensive medication guide to Exparel including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$200 patient cost share depending on medical deductible status and plan; typically billed as part of surgical facility charges through medical (not pharmacy) insurance benefit. Prior authorization required by many commercial plans. The NOPAIN Act (effective January 2025) enables separate Medicare add-on payment in outpatient surgical settings.
Estimated Cash Pricing
$285–$444 wholesale per 20 mL vial; retail prices around $444–$997 depending on vial size. No generic available. Pharmacy discount cards (GoodRx, SingleCare) do not apply — Exparel is billed through medical benefits, not pharmacy benefits.
Medfinder Findability Score
78/100
Summarize with AI
On this page
Exparel (bupivacaine liposome injectable suspension) is a long-acting, non-opioid local anesthetic manufactured by Pacira BioSciences, Inc. It uses the company's proprietary DepoFoam drug delivery technology to encapsulate bupivacaine inside multivesicular liposomes — tiny honeycomb-structured fat particles that slowly release the drug over time. A single injection provides postoperative pain relief for up to 72 hours.
Unlike standard bupivacaine, which wears off in 4–8 hours, Exparel's extended-release formulation dramatically reduces the need for opioid pain medications after surgery. It was first FDA-approved in October 2011 for surgical site infiltration and has since received approval for multiple nerve block indications in adults. Exparel is not dispensed at retail pharmacies — it is administered exclusively by surgeons, anesthesiologists, or CRNAs in hospital or surgical center settings.
There is currently no generic version of Exparel. The drug is available as a 13.3 mg/mL (1.3%) injectable suspension in 10 mL (133 mg) and 20 mL (266 mg) single-dose vials.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Exparel works through two complementary mechanisms. First, bupivacaine itself blocks sodium channels in nerve cell membranes, preventing the generation and conduction of electrical impulses that carry pain signals to the brain. This is the same basic mechanism as all amide-type local anesthetics (lidocaine, ropivacaine, mepivacaine).
What makes Exparel unique is its DepoFoam delivery system. Bupivacaine is encapsulated inside multivesicular liposomes — microscopic particles made of lipid (fat) membranes arranged in a honeycomb-like structure with multiple internal compartments. Each compartment contains a small amount of bupivacaine. After injection, these particles gradually erode and reorganize, releasing bupivacaine in a biphasic pattern: a small initial burst from the particle surface, followed by sustained release from the interior compartments over up to 72 hours.
The liposome particles range from 24 to 31 micrometers in diameter — large enough that they don't rapidly enter the bloodstream, which slows the overall release of bupivacaine and extends the duration of local analgesia. Once bupivacaine is released and absorbed systemically, it is metabolized primarily by the liver (CYP3A4 enzymes) and eliminated in urine. Systemic bupivacaine levels from Exparel can be detectable for up to 96 hours after a single dose.
133 mg/10 mL (13.3 mg/mL) — Injectable suspension
Single-dose 10 mL vial; may be used for smaller procedures or pediatric patients
266 mg/20 mL (13.3 mg/mL) — Injectable suspension
Standard single-dose 20 mL vial; maximum adult dose; most commonly used for wound infiltration and nerve blocks
Exparel is not a retail pharmacy drug. It is stocked exclusively by hospital and surgical center pharmacies and administered in the operating room. As of 2026, Exparel does not appear on the FDA's national drug shortage database — the product is commercially available from Pacira BioSciences without manufacturing disruptions.
However, access challenges exist due to hospital formulary restrictions. Exparel costs approximately $378–$444 per vial at wholesale — roughly 100 times more expensive than standard bupivacaine. Many hospital pharmacy and therapeutics committees have restricted Exparel to specific high-value procedures (total joint arthroplasty, shoulder surgery, thoracic procedures) or removed it from formulary entirely. The NOPAIN Act, effective January 2025, significantly improves the economics for Medicare outpatient cases by authorizing a separate add-on payment for Exparel — which may expand formulary access in ASCs and HOPDs over time.
To find Exparel, patients should ask their surgeon and anesthesiologist directly at the preoperative appointment and call the hospital or ASC pharmacy to confirm formulary status. For other post-surgical prescriptions that may be needed after your procedure, medfinder is a paid service that calls local pharmacies to find which ones have your medications in stock, then texts you the results.
Exparel is not a controlled substance and has no DEA scheduling requirements. However, it is an injectable drug that must be administered by a licensed healthcare provider in a clinical setting — it cannot be dispensed as a take-home prescription. The drug is stocked by hospital and surgical center pharmacies and ordered by members of the surgical team.
Healthcare providers who administer Exparel include:
Exparel is not available via telehealth prescription — it can only be administered in person in a licensed surgical or procedural facility. Patients interested in having Exparel as part of their pain management plan should discuss it with their surgeon and anesthesiology team at their preoperative consultation.
No. Exparel is not a controlled substance and is not scheduled by the Drug Enforcement Administration (DEA). Bupivacaine, the active ingredient in Exparel, is a local anesthetic — not an opioid or other drug with abuse potential. It does not produce euphoria, physical dependence, or addiction.
This non-controlled status is one of Exparel's primary advantages in surgical pain management: it can be used as an opioid-sparing or opioid-free analgesic strategy without the prescribing restrictions, monitoring requirements, or addiction risks associated with opioid pain medications like oxycodone or hydrocodone. Patients with a history of opioid use disorder, respiratory compromise, or elderly patients at high opioid risk are often specifically selected for Exparel-based pain management protocols.
Exparel is administered exclusively by licensed healthcare providers (surgeons, anesthesiologists, CRNAs) in clinical settings. It is not available as a take-home prescription and cannot be dispensed by retail pharmacies.
Common side effects reported in clinical trials of Exparel for wound infiltration include:
Serious side effects requiring emergency care:
Know what you need? Skip the search.
Standard Bupivacaine HCl (Marcaine, Sensorcaine)
Generic amide local anesthetic; same active ingredient as Exparel without extended-release formulation. Duration 4–8 hours. Cost $2–$8 per vial. Widely stocked at all hospitals.
Ropivacaine (Naropin)
Long-acting amide local anesthetic; slightly lower cardiac toxicity than bupivacaine. Generic available. Duration 4–12 hours. Widely used for nerve blocks and epidurals.
XARACOLL (Bupivacaine Collagen Implant)
Extended-release bupivacaine collagen sponge implant approved for open inguinal hernia repair in adults. Different delivery mechanism from Exparel (solid implant vs. injectable suspension).
Continuous Peripheral Nerve Block Catheter
Catheter-based technique delivering local anesthetic (ropivacaine or bupivacaine) continuously near a nerve for 1–3 days. More complex setup but allows dose adjustment. Often preferred for major orthopedic and thoracic procedures.
Prefer Exparel? We can find it.
Lidocaine (and other non-bupivacaine local anesthetics)
majorCONTRAINDICATED for admixing. Lidocaine, chloroprocaine, and mepivacaine destabilize Exparel's liposomes, causing immediate release of all encapsulated bupivacaine and potential systemic toxicity. Wait at least 20 minutes after local lidocaine administration before injecting Exparel. No other local anesthetics within 96 hours post-Exparel.
Bupivacaine HCl (Standard)
moderateCan be combined if mg ratio of HCl:Exparel does not exceed 1:2. Toxic effects are additive — monitor for CNS and cardiac signs of local anesthetic systemic toxicity (LAST).
Nitroglycerin and nitrates/nitrites
moderateIncreased risk of methemoglobinemia when coadministered. Notify surgical team of any nitrate use before receiving Exparel.
Metoclopramide (Reglan)
moderateIncreased methemoglobinemia risk when combined with bupivacaine-containing products. Alert surgical team if using metoclopramide for nausea management.
CNS Depressants (opioids, benzodiazepines, sedatives)
moderateMay worsen CNS depression, dizziness, and drowsiness associated with bupivacaine systemic absorption. Disclose all CNS depressant use to anesthesia team before surgery.
Povidone-iodine (Betadine)
moderateDirect contact between Betadine and Exparel can disrupt liposomes. Surgical site must dry completely after Betadine skin prep before Exparel is injected.
Exparel represents a meaningful advance in postoperative pain management. By providing up to 72 hours of local analgesia from a single injection — without opioids — it supports the broader healthcare goal of reducing surgical opioid dependence while improving patient recovery. Its DepoFoam technology has been well-established since its 2011 FDA approval, and its indication expansion to multiple nerve block types has broadened its utility across surgical specialties.
Access to Exparel is primarily limited by cost and formulary availability, not manufacturing shortage. The NOPAIN Act (effective January 2025) has begun to improve the reimbursement landscape for Medicare outpatient cases. Patients who believe they are good candidates for Exparel should advocate for themselves by having conversations with their surgical team at the preoperative appointment and checking with their facility's pharmacy department.
For other medications that may be part of your surgical or post-surgical care, medfinder is a paid service that calls pharmacies near you to locate in-stock medications and texts you the results — saving you the frustrating process of calling pharmacy after pharmacy while recovering from surgery.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini